Cosentyx® clinical trial program in psoriasis

- There are four pivotal trials for Cosentyx® (secukinumab) in psoriasis
- Four extension studies are exploring the long-term sustainability of Cosentyx
- Two head-to-head trials demonstrate the superiority of Cosentyx over Enbrel®* and Stelara®**
- Three trials demonstrate the efficacy of Cosentyx in difficult-to-treat scalp psoriasis, nail psoriasis, and palmoplantar psoriasis (of the hands and feet)
- More than 10,000 patients have been treated with Cosentyx across multiple indications in the clinical trial program

Pivotal trials in psoriasis

The Cosentyx clinical trial program in psoriasis was made up of 10 Phase II and Phase III studies.

Pivotal studies: strength, speed and sustainability

The approval of Cosentyx in psoriasis is based on four pivotal Phase III trials: ERASURE2, FIXTURE2, FEATURE3 and JUNCTURE4, which involved 2,403 patients with moderate-to-severe plaque psoriasis1. Across all trials, the co-primary endpoints were the proportion of patients who achieved a reduction in Psoriasis Area Severity Index (PASI) score of at least 75% (PASI 75 response) from baseline to Week 12 and treatment success (clear or almost clear skin) on the Investigator’s Global Assessment modified 2011 (IGA 0/1)1.

Results

- All primary endpoints were achieved with Cosentyx 300 mg and 150 mg

*Enbrel is a registered trademark of Amgen Inc. **Stelara is a registered trademark of Janssen Biotech Inc.
PASI 75 response achieved at Week 12

<table>
<thead>
<tr>
<th></th>
<th>150 mg</th>
<th>300 mg</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERASURE</td>
<td>72%</td>
<td>82%</td>
<td>5%</td>
</tr>
<tr>
<td>FIXTURE</td>
<td>67%</td>
<td>77%</td>
<td>5%</td>
</tr>
<tr>
<td>FEATURE</td>
<td>70%</td>
<td>76%</td>
<td>0%</td>
</tr>
<tr>
<td>JUNCTURE</td>
<td>72%</td>
<td>87%</td>
<td>3%</td>
</tr>
</tbody>
</table>

IGA mod 2011 0/1 scores (clear or almost clear skin)

<table>
<thead>
<tr>
<th></th>
<th>150 mg</th>
<th>300 mg</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERASURE</td>
<td>51%</td>
<td>55%</td>
<td>2%</td>
</tr>
<tr>
<td>FIXTURE</td>
<td>51%</td>
<td>62%</td>
<td>3%</td>
</tr>
<tr>
<td>FEATURE</td>
<td>53%</td>
<td>69%</td>
<td>0%</td>
</tr>
<tr>
<td>JUNCTURE</td>
<td>53%</td>
<td>73%</td>
<td>0%</td>
</tr>
</tbody>
</table>

- In the ERASURE study, Cosentyx was associated with a fast onset of efficacy with a 50% reduction in mean PASI response by Week Three for the 300 mg dose.

Extension studies

Results from the SCULPTURE study:
- Over the extended treatment period from Year 1 (Week 52) to the end of Year 5 (Week 260), PASI 75/90/100 response rates remained consistent.
- PASI 75 and PASI 90 response rates were achieved by 89% and 69% of psoriasis patients, respectively, at Year 1 (‘as observed’ analysis) and this high rate was maintained to Year 5 (89% and 66%, respectively).
- In addition, 44% of psoriasis patients achieved completely clear skin (PASI 100) at Year 1 and this rate was maintained to Year 5 (41%).
- Cosentyx continued to have a favorable and consistent safety profile, and low immunogenicity.

Head-to-head trials

CLEAR study: Cosentyx shows superiority to Stelara
A 52-week, randomized, double-blind, head-to-head study, in 669 patients with moderate-to-severe plaque psoriasis, comparing the efficacy, long-term safety and tolerability of Cosentyx 300 mg versus Stelara (ustekinumab, dosing per label).

Results so far:
- Cosentyx was superior to Stelara in achieving and sustaining PASI 90 response (79% versus 58%) at Week 16.
• Cosentyx remained consistently superior to Stelara in achieving and sustaining a PASI 90 response (76% versus 61%) and significantly better in achieving PASI 100 (clear skin) response (46% versus 36%) at Week 52.7
• Response rates with Cosentyx were maintained to Week 104, with a 75% PASI 90 response (compared to 78% at Week 52), and a 47% PASI 100 response (compared to 48% at Week 52).11 Cosentyx showed significantly greater and sustained DLQI 0/1 responses versus Stelara (72% versus 59%) at Week 52.†
• This remained high over two years, with 66% achieving DLQI 0/1 responses at Week 104 compared to 72% at Week 52.11
• Patients in the Stelara arm of the study discontinued after the Week 52 database lock

†Exploratory endpoints

Difficult-to-treat psoriasis

SCALP
A 24-week, randomized, double-blind, placebo-controlled study in 102 patients with moderate-to-severe scalp psoriasis to assess the safety and efficacy of Cosentyx 300 mg or 150 mg or placebo.8

TRANSFIGURE
A 128-week, randomized, double-blind, placebo-controlled study in 198 patients with moderate-to-severe psoriasis and significant nail involvement to assess the safety and efficacy of Cosentyx 300 mg or 150 mg or placebo.12

GESTURE
A 132-week, randomized, double-blind, placebo-controlled study in 201 patients with moderate-to-severe palmoplantar psoriasis to assess the safety and efficacy of Cosentyx 300 mg or 150 mg or placebo.9

Results so far:
• In the SCALP study, PSSI 90 responses were achieved by a significantly greater percentage of patients receiving Cosentyx 300 mg (52.9%) than placebo (2.0%) at Week 12 (P<0.001).8
• In the TRANSFIGURE study, a mean -38% NAPSI improvement from baseline (Nail Psoriasis Severity Index) was observed with Cosentyx 300 mg and -14% with Cosentyx 150 mg.12 At Week 32, PASI 90 responses were achieved in 72% of patients receiving Cosentyx 300 mg and 61% receiving Cosentyx 150 mg. PASI 100 responses were achieved in 37% of patients receiving Cosentyx 300 mg and 28% receiving Cosentyx 150 mg.12
• In the GESTURE study, approximately 60% of patients receiving Cosentyx 300 mg achieved clear or almost clear palms and soles with Cosentyx, as measured by ppIGA response (palmoplantar Investigator’s Global Assessment) at 1.5 years.13
Safety and tolerability

Safety

- Cosentyx has been shown to have a favorable safety profile and low immunogenicity in clinical trials across multiple indications in which more than 10,000 patients have been treated with Cosentyx. A further 100,000 patients have been treated with Cosentyx in the post-marketing setting14
- The risk-benefit assessment for Cosentyx has not changed in the post-market setting
- The most common side effects in psoriasis studies were nasopharyngitis, headache and upper respiratory tract infection1,2

The Cosentyx clinical trial program includes long-term extension studies that will continue to collect safety information and data over an extended period of time. In addition, an eight-year psoriasis registry study consisting of more than 3,000 patients exposed to Cosentyx will also provide long-term safety data13.

References

5. Bissonnette R et al. Secukinumab demonstrates high sustained efficacy and a favorable safety profile through 5 years of treatment in moderate to severe psoriasis. Presented as eposter P2223 at 26th EADV Congress 2017. 13th September 2017